58041-99-9 Usage
Uses
Used in Pharmaceutical Synthesis:
METHYL 3-[(2,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to modulate biological processes, contributing to the development of new medications.
Used in Agrochemical Production:
In the agrochemical industry, METHYL 3-[(2,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE is utilized as a component in the creation of various agrochemicals, potentially enhancing crop protection and yield.
Used in Fragrance and Flavoring Agent Manufacturing:
METHYL 3-[(2,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE is employed as a component in the production of fragrances and flavoring agents, adding to the complexity and variety of scents and tastes in consumer products.
Used in Organic Compound Preparation:
METHYL 3-[(2,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE is also used as a key intermediate in the preparation of various organic compounds, indicating its versatility in chemical reactions and synthesis processes across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 58041-99-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,0,4 and 1 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 58041-99:
(7*5)+(6*8)+(5*0)+(4*4)+(3*1)+(2*9)+(1*9)=129
129 % 10 = 9
So 58041-99-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H12Cl2O3/c1-19-15(18)10-3-2-4-13(7-10)20-9-11-5-6-12(16)8-14(11)17/h2-8H,9H2,1H3
58041-99-9Relevant academic research and scientific papers
Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors
Ndikuryayo, Ferdinand,Kang, Wei-Ming,Wu, Feng-Xu,Yang, Wen-Chao,Yang, Guang-Fu
, p. 22 - 31 (2019/01/26)
Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
